Researchers at GlaxoSmithKline (GSK) have discovered that two key measures that track symptom severity among asthmatic patients considerably improved with the use of Nucala, according to the results of a clinical trial.
Patients treated with Eli Lilly’s Taltz oral prescription medication for psoriasis showed better results than those receiving Janssen Biotech’s rival drug Stelara, according to an Eli Lilly press release.
Global biopharmaceutical company AbbVie has received priority review from the Japanese Ministry of Health, Labour and Welfare for Glecaprevir/Pibrentasvir, its drug for the treatment of chronic hepatitis C.
Horizon Pharma plc, a biopharmaceutical company, has launched UCD in Common, an effort to educate people about urea cycle disorder, a rare genetic disease characterized by toxic levels of ammonia in the blood.
Arriva Medical has applauded a district court's decision to deny a motion from Centers for Medicare & Medicaid Services (CMS) to dismiss Arriva’s complaint while expressing disappointment that it denied Arriva's motion for interim relief.
The Food and Drug Administration (FDA) has sent AstraZeneca a complete response letter (CRL) from the regulatory board in response to the development of sodium zirconium cyclosilicate, a drug designed to treat hyperkalaemia.
Legislation designed to tie U.S. Postal Service retiree health care plans more closely with Medicare could needlessly saddle seniors with two insurance premiums, according to one health policy expert who has studied a bill introduced in the U.S. House of Representatives.
About 30 to 40 percent of those deaths due to cancer could be prevented, and one-third of the cancer cases can be cured with early detection and treatment, according to the American Cancer Society (ACS).